Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug

New strategies to decrease risk of relapse after surgery are needed for improving 5‐year survival rate of hepatocellular carcinoma (HCC). To address this need, a wound‐targeted nanodrug is developed, that contains an immune checkpoint inhibitor (anti‐PD‐L1)and an angiogenesis inhibitor (sorafenib))....

Descripción completa

Detalles Bibliográficos
Autores principales: li, Bozhao, Zhang, Xiuping, Wu, Zhouliang, Chu, Tianjiao, Yang, Zhenlin, Xu, Shuai, Wu, Suying, Qie, Yunkai, Lu, Zefang, Qi, Feilong, Hu, Minggen, Zhao, Guodong, Wei, Jingyan, Zhao, Yuliang, Nie, Guangjun, Meng, Huan, Liu, Rong, Li, Suping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284141/
https://www.ncbi.nlm.nih.gov/pubmed/35524631
http://dx.doi.org/10.1002/advs.202200477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284141/
https://www.ncbi.nlm.nih.gov/pubmed/35524631
http://dx.doi.org/10.1002/advs.202200477

Ejemplares similares